BioCryst Pharmaceuticals, Inc. (BCRX) – What Are Investment Firms Thinking About This Stock?

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average rating of “Hold” from the eleven research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $19.44.

Several research analysts recently commented on the stock. Royal Bank Of Canada downgraded shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $13.00 to $11.00 in a research note on Thursday, September 10th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Wedbush lowered their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Finally, Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th.

Institutional Trading of BioCryst Pharmaceuticals

Large investors have recently modified their holdings of the company. Contravisory Investment Management Inc. purchased a new position in BioCryst Pharmaceuticals during the 3rd quarter worth $316,000. Councilor Wealth LLC raised its position in BioCryst Pharmaceuticals by 95.9% during the 3rd quarter. Councilor Wealth LLC now owns 58,774 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 28,774 shares in the last quarter. WINTON GROUP Ltd raised its position in BioCryst Pharmaceuticals by 380.3% during the 2nd quarter. WINTON GROUP Ltd now owns 255,600 shares of the biotechnology company’s stock valued at $2,556,000 after purchasing an additional 202,384 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at $108,000. Finally, IFP Advisors Inc raised its position in BioCryst Pharmaceuticals by 2,515.3% during the 2nd quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 3,119 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 0.2%

Shares of BioCryst Pharmaceuticals stock opened at $8.05 on Friday. The stock’s fifty day moving average is $9.07 and its two-hundred day moving average is $9.16. BioCryst Pharmaceuticals has a 52 week low of $6.23 and a 52 week high of $11.22. The company has a market capitalization of $2.06 billion, a PE ratio of -5.37 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The business’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period last year, the company earned $0.15 earnings per share. As a group, research analysts anticipate that BioCryst Pharmaceuticals will post -2.28 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients.